# Cognition Therapeutics Inc: financial statements, quarterly

CGTX · Nasdaq · CIK 1455365 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cgtx.md) · [Financials](/companies/cgtx/financials.md) · [Filings](/companies/cgtx/filings.md) · [Insiders](/companies/cgtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cgtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [11.7](/filings/0001558370-24-015436.md) | [11.6 d](/filings/0001558370-25-003341.md) | [10.6](/filings/0001558370-25-006612.md) | [11.6](/filings/0001558370-25-010771.md) | [11.4](/filings/0001104659-25-107402.md) | [8.2 d](/filings/0001104659-26-034880.md) | [10.8](/filings/0001104659-26-057545.md) | [11.5](/filings/0001104659-26-092362.md) | [3.8](/filings/0001104659-25-107402.md) | [11.1 d](/filings/0001104659-26-034880.md) | [6.1](/filings/0001104659-26-057545.md) | [5.1](/filings/0001104659-26-092362.md) |
| Operating income | $m | [(14.7)](/filings/0001558370-24-015436.md) | [(15.2) d](/filings/0001558370-25-003341.md) | [(14.1)](/filings/0001558370-25-006612.md) | [(14.7)](/filings/0001558370-25-010771.md) | [(14.5)](/filings/0001104659-25-107402.md) | [(10.7) d](/filings/0001104659-26-034880.md) | [(13.8)](/filings/0001104659-26-057545.md) | [(14.0)](/filings/0001104659-26-092362.md) | [(6.4)](/filings/0001104659-25-107402.md) | [(13.7) d](/filings/0001104659-26-034880.md) | [(8.8)](/filings/0001104659-26-057545.md) | [(7.7)](/filings/0001104659-26-092362.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(6.7)](/filings/0001558370-24-015436.md) | [(8.1) d](/filings/0001558370-25-003341.md) | [(9.2)](/filings/0001104659-25-107402.md) | [(7.0)](/filings/0001104659-25-107402.md) | [(9.9)](/filings/0001104659-25-107402.md) | [(7.8) d](/filings/0001104659-26-034880.md) | [(8.5)](/filings/0001104659-26-092362.md) | [(6.7)](/filings/0001104659-26-092362.md) | [(4.9)](/filings/0001104659-25-107402.md) | [(3.3) d](/filings/0001104659-26-092362.md) | [(4.6)](/filings/0001104659-26-092362.md) | [(3.9)](/filings/0001104659-26-092362.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001558370-24-015436.md) | not reported | [(0.27)](/filings/0001558370-25-006612.md) | [(0.18)](/filings/0001558370-25-010771.md) | [(0.25)](/filings/0001104659-25-107402.md) | not reported | [(0.14)](/filings/0001104659-26-057545.md) | [(0.11)](/filings/0001104659-26-092362.md) | [(0.06)](/filings/0001104659-25-107402.md) | not reported | [(0.05)](/filings/0001104659-26-057545.md) | [(0.04)](/filings/0001104659-26-092362.md) |
| Basic EPS | $ per share | [(0.22)](/filings/0001558370-24-015436.md) | not reported | [(0.27)](/filings/0001558370-25-006612.md) | [(0.18)](/filings/0001558370-25-010771.md) | [(0.25)](/filings/0001104659-25-107402.md) | not reported | [(0.14)](/filings/0001104659-26-057545.md) | [(0.11)](/filings/0001104659-26-092362.md) | [(0.06)](/filings/0001104659-25-107402.md) | not reported | [(0.05)](/filings/0001104659-26-057545.md) | [(0.04)](/filings/0001104659-26-092362.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.0](/filings/0001558370-23-017321.md) | [29.9](/filings/0001558370-25-003341.md) | [34.7](/filings/0001558370-24-006911.md) | [28.5](/filings/0001558370-25-010771.md) | [22.0](/filings/0001104659-25-107402.md) | [25.0](/filings/0001104659-26-034880.md) | [16.4](/filings/0001558370-25-006612.md) | [10.7](/filings/0001104659-26-092362.md) | [39.3](/filings/0001104659-25-107402.md) | [36.8](/filings/0001104659-26-092362.md) | [31.1](/filings/0001104659-26-057545.md) | [34.0](/filings/0001104659-26-092362.md) |
| Current assets | $m | [36.0](/filings/0001558370-23-017321.md) | [34.2](/filings/0001558370-25-003341.md) | [38.0](/filings/0001558370-24-006911.md) | [33.6](/filings/0001558370-24-011464.md) | [26.8](/filings/0001558370-24-015436.md) | [29.6](/filings/0001104659-26-034880.md) | [22.9](/filings/0001558370-25-006612.md) | [19.0](/filings/0001558370-25-010771.md) | [42.9](/filings/0001104659-25-107402.md) | [48.0](/filings/0001104659-26-092362.md) | [35.8](/filings/0001104659-26-057545.md) | [38.3](/filings/0001104659-26-092362.md) |
| Total assets | $m | [38.8](/filings/0001558370-23-017321.md) | [35.2](/filings/0001558370-25-003341.md) | [38.9](/filings/0001558370-24-006911.md) | [34.4](/filings/0001558370-24-011464.md) | [27.6](/filings/0001558370-24-015436.md) | [30.2](/filings/0001104659-26-034880.md) | [23.5](/filings/0001558370-25-006612.md) | [19.6](/filings/0001558370-25-010771.md) | [43.4](/filings/0001104659-25-107402.md) | [48.4](/filings/0001104659-26-092362.md) | [36.1](/filings/0001104659-26-057545.md) | [38.9](/filings/0001104659-26-092362.md) |
| Current liabilities | $m | [8.2](/filings/0001558370-23-017321.md) | [10.2](/filings/0001558370-25-003341.md) | [9.5](/filings/0001558370-24-006911.md) | [10.9](/filings/0001558370-24-011464.md) | [12.7](/filings/0001558370-24-015436.md) | [11.1](/filings/0001104659-26-034880.md) | [11.0](/filings/0001558370-25-006612.md) | [12.4](/filings/0001558370-25-010771.md) | [6.7](/filings/0001104659-25-107402.md) | [13.9](/filings/0001104659-26-092362.md) | [6.1](/filings/0001104659-26-057545.md) | [5.5](/filings/0001104659-26-092362.md) |
| Total liabilities | $m | [9.8](/filings/0001558370-23-017321.md) | [10.7](/filings/0001558370-25-003341.md) | [10.0](/filings/0001558370-24-006911.md) | [11.4](/filings/0001558370-24-011464.md) | [13.1](/filings/0001558370-24-015436.md) | [11.5](/filings/0001104659-26-034880.md) | [11.2](/filings/0001558370-25-006612.md) | [12.6](/filings/0001558370-25-010771.md) | [6.9](/filings/0001104659-25-107402.md) | [14.1](/filings/0001104659-26-092362.md) | [6.2](/filings/0001104659-26-057545.md) | [5.9](/filings/0001104659-26-092362.md) |
| Shareholders' equity | $m | [28.9](/filings/0001558370-24-015436.md) | [24.5](/filings/0001104659-26-034880.md) | [28.9](/filings/0001104659-25-107402.md) | [23.0](/filings/0001104659-25-107402.md) | [14.5](/filings/0001104659-25-107402.md) | [18.8](/filings/0001104659-26-092362.md) | [12.3](/filings/0001104659-26-092362.md) | [7.0](/filings/0001104659-26-092362.md) | [36.5](/filings/0001104659-25-107402.md) | [34.3](/filings/0001104659-26-092362.md) | [29.9](/filings/0001104659-26-092362.md) | [33.0](/filings/0001104659-26-092362.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,161) d](/filings/0001558370-24-015436.md) | [(5,456) d](/filings/0001558370-25-003341.md) | [(7,244)](/filings/0001558370-25-006612.md) | [(5,997) d](/filings/0001558370-25-010771.md) | [(6,851) d](/filings/0001104659-25-107402.md) | [(8,382) d](/filings/0001104659-26-034880.md) | [(9,877)](/filings/0001104659-26-057545.md) | [(5,623) d](/filings/0001104659-26-092362.md) | [(5,651) d](/filings/0001104659-25-107402.md) | [(3,437) d](/filings/0001104659-26-034880.md) | [(5,542)](/filings/0001104659-26-057545.md) | [(3,053) d](/filings/0001104659-26-092362.md) |
| Capital expenditure | $k | [58.0 d](/filings/0001558370-24-015436.md) | [30.0 d](/filings/0001558370-25-003341.md) | not reported | not reported | [0.0 d](/filings/0001104659-25-107402.md) | [1.0 d](/filings/0001104659-26-034880.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [23.0](/filings/0001558370-23-017321.md) | [29.1](/filings/0001558370-24-006911.md) | [29.6](/filings/0001558370-24-011464.md) | [30.4](/filings/0001558370-24-015436.md) | [33.7](/filings/0001558370-25-006612.md) | [40.1](/filings/0001558370-25-010771.md) | [40.4](/filings/0001104659-25-107402.md) | [61.8](/filings/0001104659-26-057545.md) | [63.7](/filings/0001104659-26-092362.md) | [78.0](/filings/0001104659-25-107402.md) | [89.2](/filings/0001104659-26-057545.md) | [90.6](/filings/0001104659-26-092362.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 95,093,746 at 2026-08-04, from the cover of the [10-Q filed 2026-08-07](/filings/0001104659-26-092362.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.